Biocon Biologics, a subsidiary of Biocon, received a European Union GMP certificate from the Health Products Regulatory Authority (HPRA), Ireland, for its new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru, India. The facility, spread across 340,000 ft2, is expected to enhance the company’s capabilities to manufacture drug products from its mAbs portfolio. The integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
Biocon Biologics is a fully integrated global biosimilars organization. Company officials say it is leveraging cutting-edge science, innovative tech platforms, and advanced research & development capabilities to lower costs of biologics therapies while improving healthcare outcomes. It has a research pipeline of biosimilar molecules across diabetes, oncology, immunology, and other non-communicable diseases. Seven molecules from Biocon Biologics’ portfolio have been commercialized in emerging and developed markets like the U.S., EU, Australia, Canada, and Japan.
Biocon Biologics has signed a strategic alliance with Serum Institute Life Sciences (subject to certain closing conditions) to address the inequitable access to life saving vaccines and biologics globally, according to a company spokesperson
